355 related articles for article (PubMed ID: 34503151)
21. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
Schwabe RF; Greten TF
J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
[TBL] [Abstract][Full Text] [Related]
22. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
Chen J; Vitetta L
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717871
[TBL] [Abstract][Full Text] [Related]
23. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
[TBL] [Abstract][Full Text] [Related]
24. Alcoholic liver disease: the gut microbiome and liver cross talk.
Hartmann P; Seebauer CT; Schnabl B
Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
[TBL] [Abstract][Full Text] [Related]
25. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?
Villard A; Boursier J; Andriantsitohaina R
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G485-G495. PubMed ID: 33471632
[TBL] [Abstract][Full Text] [Related]
26. Liver-Microbiome Axis in Health and Disease.
Adolph TE; Grander C; Moschen AR; Tilg H
Trends Immunol; 2018 Sep; 39(9):712-723. PubMed ID: 29843959
[TBL] [Abstract][Full Text] [Related]
27. Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics.
Said I; Ahad H; Said A
World J Gastrointest Oncol; 2022 May; 14(5):947-958. PubMed ID: 35646285
[TBL] [Abstract][Full Text] [Related]
28. Intestinal microbiota and nonalcoholic steatohepatitis.
Brandl K; Schnabl B
Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
[TBL] [Abstract][Full Text] [Related]
29. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
Meroni M; Longo M; Dongiovanni P
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
[TBL] [Abstract][Full Text] [Related]
30. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
31. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
Rizzetto L; Fava F; Tuohy KM; Selmi C
J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
[TBL] [Abstract][Full Text] [Related]
32. Potential mechanisms linking gut microbiota and portal hypertension.
Baffy G
Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
[TBL] [Abstract][Full Text] [Related]
33. The role of the gut microbiota in NAFLD.
Leung C; Rivera L; Furness JB; Angus PW
Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
[TBL] [Abstract][Full Text] [Related]
35. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
Ghoshal UC; Goel A; Quigley EMM
Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
[TBL] [Abstract][Full Text] [Related]
36. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
37. Microbiome-liver crosstalk: A multihit therapeutic target for liver disease.
Kirundi J; Moghadamrad S; Urbaniak C
World J Gastroenterol; 2023 Mar; 29(11):1651-1668. PubMed ID: 37077519
[TBL] [Abstract][Full Text] [Related]
38. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer.
Méndez-Sánchez N; Valencia-Rodriguez A; Vera-Barajas A; Abenavoli L; Scarpellini E; Ponciano-Rodriguez G; Wang DQ
Hepatoma Res; 2020; 6():. PubMed ID: 32582865
[TBL] [Abstract][Full Text] [Related]
39. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk.
Di Ciaula A; Baj J; Garruti G; Celano G; De Angelis M; Wang HH; Di Palo DM; Bonfrate L; Wang DQ; Portincasa P
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32823983
[TBL] [Abstract][Full Text] [Related]
40. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
